Difluoromethylornithine chemoprevention of epidermal carcinogenesis in K14-HPV16 transgenic mice

Cancer Research

Volumn 59, Issue 15, 1999, Pages 3610-3620

  Arbeit, Jeffrey M ^a,e   Riley, Rebeccah R ^a   Huey, Bing ^a   Porter, Carl ^c   Kelloff, Gary ^b   Lubet, Ronald ^b   Ward, Jerrold M ^d   Pinkel, Dan ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFLORNITHINE; ORNITHINE DECARBOXYLASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER PREVENTION; CARCINOGENESIS; CARCINOMA; DRUG SCREENING; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN CANCER; SKIN CARCINOGENESIS; TRANSGENIC MOUSE;

ADMINISTRATION, ORAL; ANIMALS; ANTICARCINOGENIC AGENTS; CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; DNA REPLICATION; EAR; EFLORNITHINE; EPIDERMIS; GENE EXPRESSION REGULATION; GENES, VIRAL; KERATIN-14; KERATINS; MICE; MICE, TRANSGENIC; NEOPLASM PROTEINS; ORGAN SPECIFICITY; ORNITHINE DECARBOXYLASE; PAPILLOMA; PAPILLOMAVIRIDAE; PRECANCEROUS CONDITIONS; PUTRESCINE; SKIN DISEASES; SKIN NEOPLASMS; THORAX; TRANSGENES;

EID: 0033178725     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Greenwald, P. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials. J. Cell. Bioohem., 25S: 29-36, 1996.
2. Morse, M., and Stoner, G. Cancer chemoprevention: principles and prospects. Carcinogenesis (Lond.), 14: 1737-1746, 1993.
3. Boone, C., and Kelloff, G. Intraepithelial neoplasia, surrogate endpoint biomarkers, and cancer chemoprevention. J. Cell. Biochem., 17: 37-48, 1993.
4. Kelloff, G., Johnson, J., Crowell, J., Boone, C., DeGeorge, J., Steele, V., Mehta, M., Temeck, J., Schmidt, W., Burke, G., Greenwald, P., and Temple, R. Approaches to the development and marketing approval of drugs that prevent cancer. Cancer Epidemiol. Biomark. Prev., 4: 1-10, 1995.
5. Mitchell, M., Hittelman, W., Lotan, R., Nishioka, K., Tortolero-Luna, G., Richards-Kortum, R., Wharton, J., and Hong, W. Chemoprevention trials and surrogate end point biomarkers in the cervix. Cancer (Phila.), 76: 1956-1977, 1995.
6. Steele, V., Moon, R., Lubet, R., Grubbs, C., Reddy, B., Wargovich, M., McCormick, D., Pereira, M., Crowell, J., Bagheri, D., Sigman, C., Boone, C., and Kelloff, G. Preclinical efficacy evaluation of potential chemopreventive agents in animal carcinogenesis models: methods and results from the NCI chemoprevention drug development program. J. Cell. Biochem., 20S: 32-54, 1994.
7. Thompson, H., and Ronan, A. Effect of D,L-2-difluoromethylornithine and endocrine manipulation on the induction of mammary carcinogenesis by 1-methyl-1-nitrosourea. Carcinogenesis (Lond.), 7: 2003-2006, 1986.
8. Ip, C., and Thompson, H. New approaches to cancer chemoprevention with difluoromethylornithine and selenite. J. Natl. Cancer Inst., 81: 839-843, 1989.
9. Samma, S., Uchida, K., Seidenfeld, J., and Oyasu, R. Effects of α-difluoromethylornithine on the development of deeply invasive urinary bladder carcinomas in mice. Urol. Res., 18: 277-280, 1990.
10. Moon, R., Detrisac, C., Thomas, C., and Kelloff, G. Chemoprevention of experimental bladder cancer. J. Cell. Biochem., 161S: 134-138, 1992.
11. Moon, R., Kelloff, G., Detrisac, C., Steele, V., Thomas, C., and Sigman, C. Chemoprevention of OH-BBN-induced bladder cancer in mice by oltipraz, alone and in combination with 4-HPR and DFMO. Anticancer Res., 14: 5-12, 1994.
12. Zhang, S., Luk, G., and Hamilton, S. α-Difluoromethylornithine-induced inhibition of growth of autochthonous experimental colonic tumors produced by azoxymethane in male F344 rats. Cancer Res., 48: 6498-6503, 1988.
13. Tempero, M., Nishioka, K., Knott, K., and Zetterman, R. Chemoprevention of mouse colon tumors with difluoromethylornithine during and after carcinogen treatment. Cancer Res., 49: 5793-5797, 1989.
14. Reddy, B., Nayini, I., Tokumo, K., Rigotty, J., Zang, E., and Kelloff, G. Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with D,L-α-difluoromethylornithine, an ornithine decarboxylase inhibitor, in the diet. Cancer Res., 50: 2562-2568, 1990.
15. Singh, J., Kelloff, G., and Reddy, B. Intermediate biomarkers of colon cancer: modulation of expression of ras oncogene by chemopreventive agents during azoxymethane induced colon carcinogenesis. Carcinogenesis (Lond.), 14: 669-704, 1993.
16. Weeks, C., Herrmann, A., Nelson, F., and Slaga, T. α-Difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, inhibits tumor promoter-induced polyamine accumulation and carcinogenesis in mouse skin. Proc. Natl. Acad. Sci. USA, 79: 6028-6032, 1982.
17. Takigawa, M., Verma, A., Simsiman, R., and Boutwell, R. Inhibition of mouse skin tumor promotion and of promoter-stimulated epidermal polyamine biosynthesis by α-difluoromethylornithine. Cancer Res., 43: 3732-3738, 1983.
18. Heston, W., Fleischmann, J., Tackett, R., and Ratliff, T. Effects of α-difluoromethylornithine and recombinant interferon-α2 on the growth of a human renal cell adenocarcinoma xenograft in nude mice. Cancer Res., 44: 3220-3225, 1984.
19. Upp, J., Beauchamp, R., Townsend, C., Barranco, S., Singh, P., Rajaraman, S., James, E., and Thompson, J. Inhibition of human gastric adenocarcinoma xenograft growth in nude mice by α-difluoromethylornithine. Cancer Res., 48: 3265-3269, 1988.
20. Hanahan, D. Dissecting multi-stage tumorigenesis using transgenic mice. Annu. Rev. Genet., 22: 479-519, 1988.
21. Chin, L., Pomerantz, J., Polsky, D., Jacobson, M., Cohen, C., Cordon-Cardo, C., Horner, J. W., and DePinho, R. A. Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev., 11: 2822-2834, 1997.
22. Boolbol, S., Dannenberg, A., Chadbum, A., Martucci, C., Guo, X., Ramonetti, J., Abreu-Goris, M., Newmark, H., Lipkin, M., DeCosse, J., and Bertagnolli, M. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res., 56: 2556-2560, 1996.
23. Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res., 56: 710-714, 1996.
24. Perl, A., Wilgenbus, P., Dahl, U., Semb, H., and Christofori, G. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature (Lond.), 392: 190-193, 1998.
25. Takaku, K., Oshima, M., Miyoshi, H., Matsui, M., Seldin, M., and Taketo, M. Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes. Cell, 92: 645-656, 1998.
26. Δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87: 803-809, 1996.
27. Arbeit, J. M., Münger, K., Howley, P., and Hanahan, D. Progressive squamous epithelial neoplasia in K-14-human papillomavirus type 16 transgenic mice. J. Virol., 68: 4358-4368, 1994.
28. Coussens, L., Hanahan, D., and Arbeit, J. M. Genetic susceptibility, alterations in differentiation, and invasion during multi-stage squamous carcinogenesis in K14-HPV16 transgenic mice. Am. J. Pathol., 149: 1899-1917, 1996.
29. Smith-McCune, K., Zhu, Y., Hanahan, D., and Arbeit, J. M. Cross-species comparison of angiogenesis during the premalignant stages of squamous carcinogenesis in the human cervix and K14-HPV16 transgenic mice. Cancer Res., 57: 1294-1300, 1997.
30. Takigawa, M., Verma, A., Simsiman, R., and Boutwell, R. Polyamine biosynthesis and skin tumor promotion: inhibition of 12-O-tetradecanoylphorbol-13-acetate-promoted mouse skin tumor formation by the irreversible inhibitor of ornithine decarboxylase α-difluoromethylornithine. Biochem. Biophys. Res. Commun., 105: 969-976, 1982.
31. Gilmour, S., Verma, A., Madara, T., and O'Brien, T. G. Regulation of ornithine decarboxylase gene expression in mouse epidermis and epidermal tumors during two-stage tumorigenesis. Cancer Res., 47: 1221-1225, 1987.
32. Megosh, L., Gilmour, S., Rosson, D., Soler, A., Blessing, M., Sawicki, J., and O'Brien, T. G. Increased frequency of spontaneous skin tumors in transgenic mice which overexpress ornithine decarboxylase. Cancer Res., 55: 4205-4209, 1995.
33. O'Brien, T. G., Megosh, L., Gilliard, G., and Soler, A. Ornithine decarboxylase overexpression is a sufficient condition for tumor promotion in mouse skin. Cancer Res., 57: 2630-2637, 1997.
34. Hurlin, P., Foley, K., Ayer, D., Eisenman, R., Hanahan, D., and Arbeit, J. M. Regulation of Myc and Mad during differentiation and HPV-associated tumorigenesis. Oncogene, 11: 2487-2501, 1995.
35. Arbeit, J. M., Olson, D., and Hanahan, D. Upregulation of fibroblast growth factors and their receptors during multi-stage epidermal carcinogenesis in K14-HPV16 transgenic mice. Oncogene, 13: 1847-1857, 1996.
36. Arbeit, J. M., Howley, P., and Hanahan, D. Chronic estrogen induced cervical and vaginal squamous carcinogenesis in HPV16 transgenic mice. Proc. Natl. Acad. Sci. USA, 93: 2930-2935, 1996.
37. Reavis, F., and Contario, J. High performance liquid chromatographic assay for α-difluoromethylornithine in rodent feed. J. Liquid Chromatog., 7: 2179-2191, 1984.
38. Hogan, B., Beddington, R., Costantini, F., and Lacy, E. Manipulating the Mouse Embryo, Ed. 2, pp. 217-251. Cold Spring Harbor, NY: Cold Spring Harbor Press, 1994.
39. Naik, P., Karrim, J., and Hanahan, D. The rise and fall of apoptosis during multistage carcinogenesis: down modulation contributes to tumor progression from angiogenic progenitors. Genes Dev., 10: 2105-2116, 1996.
40. Pietilä, M., Alhonen, L., Halmekytö, M., Kanter, P., Jänne, J., and Porter, C. W. Activation of polyamine catabolism profoundly alters tissue polyamine pools and affects hair growth and female fertility in transgenic mice overexpressing spermidine/ spermine N-acetyltransferase. J. Biol. Chem., 272: 18746-18751, 1997.
41. Kramer, D., Mett, H., Evans, A., Regenass, U., Diegelman, P., and Porter, C. W. Stable amplification of the S-adenosylmethionine decarboxylase gene in Chinese hamster ovary cells. J. Biol. Chem., 270: 2124-2132, 1995.
42. Potten, C., and Loeffler, M. Stem Cells: attributes, cycles, spirals, pitfalls, and uncertainties. Lessons for and from the crypt. Development (Camb.), 110: 1001-1020, 1990.
43. Pegg, A. Polyamine metabolism and its importance in neoplastic growth and as a target for chemotherapy. Cancer Res., 48: 759-774, 1988.
44. Peralta-Soler, A., Gilliard, G., Megosh, L., George, K., and O'Brien, T. G. Polyamines regulate expression of the neoplastic phenotype in mouse skin. Cancer Res., 58: 1654-1659, 1998.
45. Arbeit, J. M. Transgenic models of epidermal neoplasia and multi-stage carcinogenesis. Cancer Surv., 26: 7-34, 1996.
46. Mamont, P. S., Danzin, C., Wagner, J., Siat, M., Joder-Ohlenbusch, A-M., and Claverie, N. Accumulation of decarboxylated S-adenosylmethionine in mammalian cells as a consequence of the inhibition of putrescine synthesis. J. Biochem., 123: 499-504, 1982.
47. Fuchs, E. Epidermal differentiation: the bare essentials. J. Cell. Biol., 111: 2807-2814, 1990.
48. DiGiovanni, J. Multistage carcinogenesis in mouse skin. Pharmocol. Ther., 54: 63-128, 1992.
49. Brown, K., Strathdee, D., Bryson, S., Lambie, W., and Balmain, A. The malignant capacity of skin tumours induced by expression of a mutant H-ras transgene depends on the cell type targeted. Curr. Biol., 8: 516-524, 1998.
50. Burns, F. Mouse skin papillomas as a stage in cancer progression. Skin Carcinogenesis: Mechanisms and Human Relevance, pp. 81-93. New York: Alan R. Liss, Inc., 1989.
51. Hennings, H., Shores, R., Mitchell, P., Spangler, E., and Yuspa, S. Induction of papillomas with a high probability of conversion to malignancy. Carcinogenesis (Lond.), 6: 1607-1610, 1985.
52. Greenhalgh, D., and Roop, D. R. Dissecting molecular carcinogenesis: development of transgenic mouse models by epidermal gene targeting. Adv. Cancer Res., 64: 247-296, 1994.
53. Brown, K., and Balmain, A. Transgenic mice and squamous multistage skin carcinogenesis. Cancer Metastasis Rev., 14: 113-124, 1995.
54. Greenhalgh, D., Wang, X-J., Rothnagel, J. A., Eckhardt, J. N., Quintanella, M. I., Barber, J. L., Bundman, D. S., Longley, M. A., Schlegel, R., and Roop, D. R. Transgenic mice expressing targeted HPV-18 E6 and E7 oncogenes in the epidermis develop verrucous lesions and spontaneous, ras-HA-activated papillomas. Cell Growth Differ., 5: 667-675, 1994.
55. Binder, R., Johnson, G., Gallagher, P., Stockman, S., Sundberg, J., and Conti, C. Squamous cell hyperplastic foci: precursors of cutaneous papillomas induced in SENCAR mice by a two-stage carcinogenesis regimen. Cancer Res., 58: 4314-4323, 1998.
56. Bickenbach, J. Identification and behavior of label-retaining cells in oral mucosa and skin. J. Dent. Res., 60: 1611-1620, 1981.
57. Gilmour, S., Robertson, F., Megosh, L., O'Connell, S., Mitchell, J., and O'Brien, T. G. Induction of ornithine decarboxylase in specific subpopulations of murine epidermal cells following multiple exposures to 12-O-tetradecanoylphorbol-13-acetate, mezerein and ethyl phenylpropriolate. Carcinogenesis (Lond.), 13: 51-56, 1992.
58. Ha oncogene in mouse skin carcinogenesis. Carcinogenesis (Lond.), 12: 1119-1124, 1991.
59. Cotsarelis, G., Sun, T., and Lavker, R. Label-retaining cells reside in the bulge area of pilosebaceous unit: implications for follicular stem cells, hair cycle, and skin carcinogenesis. Cell, 61: 1329-1337, 1990.
60. Jones, P. H. Epithelial stem cells. BioEssays, 19: 683-690, 1997.
61. Potten, C., and Morris, R. Epithelial stem cells in vivo. J. Cell. Sci. Suppl., 10: 45-62, 1988.
62. Romjin, J. C., Verkoelen, C. F., and Splinter, T. A. W. Problems of pharmacokinetic studies on α-difluoromethylornithine in mice. Cancer Chemother. Pharmacol., 19: 30-34, 1987.
63. Peña, A., Reddy, C., Wu, S., Hickok, N., Reddy, E., Yumet, G., Soprano, D., and Soprano, K. Regulation of human ornithine decarboxylase expression by the c-Myc/ Max protein complex. J. Biol. Chem., 268: 27277-27285, 1993.
64. Walhout, A., Gubbels, J., Bernards, R., van der Vliet, P., and Timmers, H. c-Myc/ Max heterodimers bind cooperatively to the E-box sequences located in the first intron of the rat ornithine decarboxylase (ODC) gene. Nucleic Acids Res., 25: 1493-1501, 1997.
65. Bello-Fernandez, C., Pakcham, G., and Cleveland, J. The ornithine decarboxylase gene is a transcriptional target of c-Myc. Proc. Natl. Acad. Sci. USA, 90: 7804-7808, 1993.
66. Pietenpol, J., Stein, R., Moran, E., Yaciuk, P., Schlegel, R., Lyons, R., Pittelkow, M., Münger, K., Howley, P. M., and Moses, H. TGF-β1 inhibition of c-myc transcription and growth in keratinocytes is abrogated by viral transforming proteins with pRB binding domains. Cell, 61: 777-785, 1990.